Efgartigimod Alfa

Phase 2

argenx SE (ARGX)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

ARGXPhase 2$58.8B

Efgartigimod Alfa Phase 2 Est. Readout

Efgartigimod Alfa• Optic Neuritis20

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Optic Neuritis

View Full Landscape

Drug Information

Target Indication

Optic Neuritis

Clinical Trial

NCT06453694

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/10/2022

Vyvgart

Vyvgart is indicated as- an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are antiacetylcholine receptor (AChR) antibody positive.- monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ARGX

argenx SE

Biological Products, (No Diagnostic Substances)•Europe•NASDAQ

Related Pipeline

ARGX-113Phase 3

Pemphigus Vulgaris

Efgartigimod PH20 SCPhase 3